Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Stricter success criteria, qualitative and quantitative end-points: acute versus prevention trials 

Stricter success criteria, qualitative and quantitative end-points: acute versus prevention trials
Chapter:
Stricter success criteria, qualitative and quantitative end-points: acute versus prevention trials
Author(s):

Peer Tfelt-Hansen

DOI:
10.1093/med/9780199552764.003.0004
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 May 2022

Chapter 4 discusses how migraine can be regarded as an episodic-chronic disorder and in the treatment of migraine one should consider treatment of the migraine attacks and in many cases also preventive treatment, addressing the current status of success criteria with the specific acute antimigraine drugs, the 5-HT1B/1D receptor agonists, the triptans.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.